First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Piha-Paul SA, Xu B, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon JA, Tsimberidou AM, Raghav K, Ajani JA, Conley AP, Mott F, Fan Y, Fan J, Peng P, Wang H, Ni S, Sun C, Qiang X, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM.
Piha-Paul SA, et al. Among authors: javle mm.
Oncologist. 2024 Apr 4;29(4):e514-e525. doi: 10.1093/oncolo/oyad338.
Oncologist. 2024.
PMID: 38297981
Free PMC article.
Clinical Trial.